Clinical Trial Update: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selinexor with chidamide for relapsed/refractory acute myeloid leukemia is in progress, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Chidamide (chidamide)
• Selinexor (selinexor)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia (Relapsed/Refractory) | Phase 2 | Status: UNKNOWN